<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136223</url>
  </required_header>
  <id_info>
    <org_study_id>BERTHA_IM101-839</org_study_id>
    <nct_id>NCT04136223</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression</brief_title>
  <acronym>BERTHA</acronym>
  <official_title>BERTHA Study: Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression. A Multicenter, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DASA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BERTHA study´s primary objective is to characterize Rheumatoid Arthritis-associated&#xD;
      Interstitial Lung Disease (RA-ILD) progression and to define a combination of biomarkers,&#xD;
      genetic and clinical variables capable of identifying patients at risk of RA-ILD progression&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BERTHA is a multicentric, observational study that will enroll 100 RA-ILD patients to be&#xD;
      followed for 2 years.&#xD;
&#xD;
      Interstitial Lung Disease (ILD) progression will be ascertained by quantitative image&#xD;
      analysis and functional parameters. Variables associated with progression with be identified.&#xD;
&#xD;
      Additionally, RA-ILD endotypes will be investigated as well as their association with RA-ILD&#xD;
      progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Lung Disease progression - FVC</measure>
    <time_frame>2 years</time_frame>
    <description>FVC longitudinal behavior (continuous variable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial Lung Disease progression - imaging</measure>
    <time_frame>2 years</time_frame>
    <description>quantitative overall disease progression (continuous variable) &amp; %VRS (vessel related structures) &gt; 4.4% if access to CALIPER software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Lung Disease progression - death</measure>
    <time_frame>2 years</time_frame>
    <description>Time to death or lung transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Lung Disease progression - FVC dichotomous variable</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with a change from baseline in the %Forced Vital Capacity (FVC):&#xD;
greater or equal to 10% or&#xD;
between 5 and 10% and worsening of symptoms</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Lung</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>RA-ILD</arm_group_label>
    <description>Consecutive adult patients (aged &gt;18 years) with RA* and interstitial lung disease&#xD;
*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        RA-ILD patients defined by altered imaging and associated functional derangements and/ or&#xD;
        symptoms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consecutive adult patients (aged &gt;18 years) meeting RA diagnostic criteria in&#xD;
             accordance with ACR 2010&#xD;
&#xD;
          2. Presence of interstitial lung disease 2.1 ILD Definition: presence of interstitial&#xD;
             alterations in HRCT associated to functional derangements and/or symptoms&#xD;
&#xD;
          3. Patient agrees with having follow-up visits every 6 months for 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or intending to become pregnant&#xD;
&#xD;
          2. Overlap with other diseases that occurs with ILD (other collagenoses, vasculitis,&#xD;
             inflammatory bowel disease)&#xD;
&#xD;
          3. Presence of advanced ILD, characterized by:&#xD;
&#xD;
             a. Dyspnea rated as modified Medical Research Council 4 (mMRC4) on routine visit&#xD;
&#xD;
          4. Presence of significant Arterial Pulmonary Hypertension:&#xD;
&#xD;
               1. Evidence of Right ventricular failure evidence by echocardiography&#xD;
&#xD;
               2. Previous right chamber catheterism showing cardiac index &lt; 2 liters/min/m²&#xD;
&#xD;
          5. Significant co-morbidity impacting respiratory system (e.g., congestive heart failure,&#xD;
             lung neoplasm, active tuberculosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Latini, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Santa Catarina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leticia Kawano Dourado, MD</last_name>
    <phone>+55 11 3053-6611</phone>
    <phone_ext>8209</phone_ext>
    <email>ldourado@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debora Kodama, BA/BS</last_name>
    <phone>+55 11 3053-6611</phone>
    <phone_ext>8209</phone_ext>
    <email>dhkodama@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Regional de Sobradinho</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <zip>70297-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Muniz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luciana Muniz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário de Brasilia (HUB)</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <zip>70840-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Licia Mota, MD</last_name>
    </contact>
    <investigator>
      <last_name>Licia Mota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas (UNICAMP)</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-872</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alisson Pugliesi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alisson Pugliesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Bonfiglioli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karina Bonfiglioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Under development</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

